Drometa 4mg/5ml Infusion

✔️ Dosage & Administration of Drometa 4mg/5ml Infusion

Hypercalcemia of Malignancy:

Recommended Dose: 4 mg as a single IV infusion over a minimum of 15 minutes.

Retreatment may be considered after 7 days if calcium levels do not normalize.

Multiple Myeloma & Bone Metastases from Solid Tumors:

Dose: 4 mg IV every 3 to 4 weeks.

Supplementation: Patients should take 500 mg of calcium and 400 IU of vitamin D orally every day.

Renal Impairment Dosage Adjustments:

• CrCl > 60 mL/min: 4 mg (5.0 mL)
• CrCl 50–60 mL/min: 3.5 mg (4.4 mL)
• CrCl 40–49 mL/min: 3.3 mg (4.1 mL)
• CrCl 30–39 mL/min: 3.0 mg (3.8 mL)
• CrCl <30 mL/min: Contraindicated

Renal impairment: Avoid use if CrCl <30 mL/min. Use adjusted dose based on renal function for CrCl 30–60 mL/min.

Elderly: No specific dose adjustment, but hydration and renal function monitoring are crucial.

✔️ Adverse Effects of Drometa 4mg/5ml Infusion

Common side effects include:

Headache, nausea, vomiting, anorexia, and fatigue

Flu-like symptoms, fever, bone pain, and muscle aches (myalgia)

Electrolyte imbalances: hypocalcemia, hypophosphatemia, hypomagnesemia

Osteonecrosis of the jaw (ONJ) (rare but serious)

Anemia, constipation, and arthralgia

✔️ Pregnancy & Lactation

Pregnancy Category D: Contraindicated due to potential harm to the fetus.

Not recommended during breastfeeding, as excretion in human milk and effects on the infant are unknown.

✔️ Precautions & Warnings

• Ensure adequate hydration before administering the drug—especially in elderly patients or those on diuretics.
• Monitor renal function closely, especially with prolonged use or in patients with risk factors.
• Serum calcium, phosphate, magnesium, and potassium levels should be regularly monitored.
• Patients with existing mineral imbalance may require correction and supplementation.
• Use with caution in patients with asthma sensitive to aspirin, as bronchoconstriction may occur.

✔️ Preparation & Infusion Guidelines

• Dilution: Dilute the required dose in 100 mL of calcium-free IV fluids (0.9% sodium chloride or 5% dextrose).
• Infusion Time: Administer over no less than 15 minutes.
• If diluted solution is not used immediately, it must be stored at 2–8°C for a maximum of 24 hours. Bring to room temperature before administration.
• Do NOT mix Zoledronic acid with calcium-containing solutions (e.g., Ringer’s lactate).
• Use a separate infusion line for this medication.

✔️ Reconstitution

Reconstitute the dose in 100 mL of 0.9% sodium chloride or 5% dextrose.

Infuse over 15 minutes using a separate IV line.

✔️ Contraindications

Known hypersensitivity to Zoledronic acid, other bisphosphonates, or excipients.

• Severe renal impairment (CrCl <30 mL/min).
• Pregnant or breastfeeding women.

Pediatric use (under 18 years) is not recommended.

✔️ Drug Interactions

Aminoglycosides may synergistically increase the risk of prolonged hypocalcemia.

Loop diuretics can exacerbate the risk of hypocalcemia.

Thalidomide may increase the risk of renal toxicity when used with Zoledronic acid.

Exercise caution when combined with other nephrotoxic agents.

✔️ Storage

• Store the vial below 30°C before opening.
• Protect from light and moisture.
• After dilution, use immediately or store at 2–8°C for up to 24 hours.
• Keep out of reach of children.